The UK’s AstraZeneca signed a deal with Shenzhen-based BioKangtai to cooperate on R&D, production and supply of the Oxford-AstraZeneca COVID19 vaccine in the Chinese mainland. BioKangtai will expand its annual production capacity to 100 million doses, reports said.
